eTopical Precious Finds
A peptide is a chain of amino acids joined by peptide bonds. That is the entire chemical definition, and it explains why the word turns up in so many unrelated places. It describes a size and a structure, the way “alloy” describes a kind of metal. It says nothing about whether a compound is approved, tested, safe or well made. Readers who treat it as a quality mark are reading something into the label that was never printed there.
A size category, not a seal of approval
Human cells build both proteins and peptides from the same twenty standard amino acids. What separates them is length. Textbooks draw the line in different places, and a cutoff near 50 amino acids is common, but nobody polices it. Insulin shows how loose the boundary is. It contains 51 amino acids split across two chains of 21 and 30, so some sources call it a peptide hormone and others call it a small protein. Both descriptions are defensible.
Much shorter chains are everywhere. Glutathione, which cells make for themselves, is only three amino acids long. Aspartame, the sweetener in many diet drinks, is built from two, aspartic acid and phenylalanine. Nobody drinks a diet soda and draws conclusions about drug approval because the sweetener is related to peptides. The same restraint belongs in front of a laboratory catalogue.
One word, four very different legal lives
Insulin was given to a human patient for the first time in Toronto in 1922. Today it is manufactured under strict pharmaceutical controls, and every product on the market carries its own regulatory approval.
Ziconotide began as a toxin. It is a synthetic, 25-amino-acid version of a peptide found in the venom of a marine cone snail, Conus magus, and FDA approved it in 2004 for severe chronic pain. A venom component became a medicine only after years of clinical work, and the approval covers the use that work supported, nothing wider.
Semaglutide and tirzepatide are peptide-based prescription medicines that FDA approved after large clinical programs. In both cases approval attaches to a finished product, meaning a specific formulation from a specific manufacturer for specific indications. It does not travel with the molecule’s name. A vial that carries the same chemical name from another source is not covered by someone else’s approval.
The fourth group is compounds sold only for laboratory work, with no approval for human use from any regulator. They are peptides too. The word is identical and the legal situation could not be more different.
Approval, where it exists, rests on three things: trial evidence for a defined use, inspection of how the product is made, and labeling that says what it is for. A compound with no approval has none of the three on file with the regulator.
Approval, compounding and “research use” are three separate questions
People collapse these into one question, and the collapse is where most of the confusion starts.
Approval means FDA reviewed evidence of safety and effectiveness for a defined use. Compounding eligibility is a narrower administrative matter: whether a pharmacy may prepare a medicine from a given bulk substance under section 503A of the Federal Food, Drug, and Cosmetic Act. FDA sorts nominated substances into categories on its interim bulks list. In 2023 it put a group of peptides in Category 2, which flags potential significant safety risks. In April 2026 it moved twelve of them out of that category after their nominations were withdrawn, and law firm commentary from Frier Levitt noted that leaving Category 2 does not by itself make a substance eligible for compounding.
The picture kept moving. A client alert from the law firm McDermott reports that FDA’s Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 and recommended adding several peptides to the 503A list. An advisory vote is a recommendation, not a final decision, and even a listed substance would not become an approved drug. Anyone quoting a peptide’s regulatory status from memory, or from a page that carries no date, is probably quoting something that has already changed.
“Research use only” is the third piece and the weakest. It is the seller’s own description of its product. It creates no approval, certifies no purity, and settles nothing about how a regulator would view a particular sale. Treat it as information about the seller, not about the compound.
Same name on the label, different contents in the vial
Synthetic peptides are usually made by solid-phase synthesis, a method Bruce Merrifield introduced in the early 1960s and that won him the 1984 Nobel Prize in Chemistry. The chain grows one amino acid at a time while anchored to a resin. Each coupling step is very good but not perfect, so a finished batch contains the target chain along with truncated and mis-built relatives. Chemists remove most of them by purification, and what remains is measured.
That measurement is where a purity percentage comes from. Chromatography, usually HPLC, reports what share of the detected material is the target. It does not prove the target is what the label says, which takes a second method such as mass spectrometry. It also says little about how much of the powder in the vial is peptide as opposed to water and leftover salts. Two vials with the same name and the same headline percentage can differ in what they actually contain, and only a lot-specific report lets a reader see how.
What a catalogue page can and cannot tell you
Catalogue pages flatten all of these differences. Costa Rica-based storefronts such as peptides.co.cr list compounds from very different regulatory categories in the same layout, under the same kind of heading. Each card shows a name, a category and a choice of strengths. None of that tells a reader which compound is an approved prescription drug somewhere, which is still under investigation and which has no approval anywhere.
Spanish-speaking readers who want to test this can open the Spanish-language research peptide catalog, pick any product and write down what the page alone establishes about its status, its testing and its source. The exercise takes a few minutes and makes the gap between a label and evidence easy to see.
Four questions that turn a label into evidence
A short checklist does more than any adjective on a product page.
- Which exact compound is this, and what is its regulatory status in the country where it would be handled? Look for a dated record from the regulator itself, not a retailer’s summary, because status has changed several times this year.
- Is there a lot-specific analytical report that matches the lot number on the vial? Purity comes from chromatography, identity needs a second method such as mass spectrometry, and a report that shows only one of them answers half the question.
- Who ran the analysis, and do they have any stake in the sale? A laboratory the seller owns is a weaker witness than an outside one with a name, a date and a method on the page.
- Does the seller stay with research language, or does the page drift into talk of treating conditions? Therapeutic claims belong to approved medicines, so a research catalogue that makes them is describing something it has no standing to describe.
Beyond those four, find out who runs the catalogue. A real business has an about page that names the company and says where it operates. The Peptides CR about page is where that catalogue describes itself, and any seller a reader considers should offer at least that much.
Why Costa Rican readers face the same gap
In Costa Rica, medicines marketed as treatments are registered with the Ministerio de Salud, and a catalogue that calls its goods research materials is not a substitute for that registration. Readers there face the same distance between a chemical name and a regulatory status as readers in the United States, with a different authority to ask. The practical step is identical in both places: go to the regulator’s own record, check its date, and compare it with what the seller says.
Where to start
Next time a page leads with the word peptide, read it as the start of a question. The answers sit in three places the word cannot replace: a regulator’s current record, a lot-specific analytical report and a named company behind the page. If a page supplies none of them, the label is all there is.
